Limosilactobacillus reuteri

2 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funder: Chinese Academy of Medical Sciences
3 of 5 findings with company ties

Model organisms2

Outcomes

Lifespan

upin flies1upin worms1

2 studies

Limosilactobacillus reuteri extends lifespan in flies.
“strain DSM 17,938 extended lifespan regardless of Gnmt”
Model organismsin irradiated fliesDSM 17938
Host Gnmt coordinates with Limosilactobacillus reuteri to alleviate ionizing radiation injury via microbiota remodeling and metabolic regulation in Drosophila melanogaster
Archives of microbiology7 Aug 2026
Limosilactobacillus reuteri extends lifespan in worms (+5 days).
“only L. paracasei LPC1114 and L. reuteri PBS072 extended the maximum lifespan by 4 and 5 days, respectively”
Model organismsin Caenorhabditis elegans
Probiotic Modulation in Aging: Strain-Specific Geroprotective Effects in Caenorhabditis elegans
International journal of molecular sciences20 Nov 2025